Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PARI is a leading global developer and manufacturer of advanced inhalation systems and medical devices for the treatment of respiratory diseases. The company is best known for its high-performance nebulizers, such as the PARI LC SPRINT and the eFlow Technology platform, which utilize vibrating mesh technology to deliver medications efficiently to the lungs. Through its subsidiary PARI Pharma, the company collaborates with pharmaceutical partners to develop drug-device combination products for indications like cystic fibrosis and nontuberculous mycobacterial lung disease. Founded in 1906 and headquartered in Germany, PARI remains a family-owned business with a significant international presence, providing essential therapy solutions for patients with chronic respiratory conditions. Its products are widely used in clinical trials and are considered a gold standard for aerosol delivery in the pharmaceutical industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pari Respiratory Equipment.